tbuckley/cabot-search huggingface dataset:
Fluoxetine ameliorates mucopolysaccharidosis type IIIA
Authors: Antonella Capuozzo, Sandro Montefusco, Vincenzo Cacace, Martina Sofia, Alessandra Esposito, Gennaro Napolitano, Eduardo Nusco, Elena Polishchuk, Maria Teresa Pizzo, Maria De Risi, Elvira De Leonibus, Nicolina Cristina Sorrentino, Diego Luis Medina
Journal: Molecular Therapy (2022)

Mucopolysaccharidosis type IIIA (MPS-IIIA) is an autosomal recessive disorder caused by mutations in SGSH involved in the degradation of heparan sulfate. MPS-IIIA presents severe neurological symptoms such as progressive developmental delay and cognitive decline, for which there is currently no treatment. Brain targeting represents the main challenge for therapeutics to treat MPS-IIIA, and the development of small-molecule-based treatments able to reach the CNS could be a relevant advance for therapy. Using cell-based high content imaging to survey clinically approved drugs in MPS-IIIA cells, we identified fluoxetine, a selective serotonin reuptake inhibitor. Fluoxetine increases lysosomal and autophagic functions via TFEB activation through a RagC-dependent mechanism. Mechanistically, fluoxetine increases lysosomal exocytosis in mouse embryonic fibroblasts from MPS-IIIA mice, suggesting that this process may be responsible for heparan sulfate clearance. In vivo, fluoxetine ameliorates somatic and brain pathology in a mouse model of MPS-IIIA by decreasing the accumulation of glycosaminoglycans and aggregated autophagic substrates, reducing inflammation, and slowing down cognitive deterioration. We repurposed fluoxetine for potential therapeutics to treat human MPS-IIIA disease.
Article on Primary Acute Lymphoblastic Leukemia Cells Using a Novel Promoter
Journal: Clinical Cancer Research (2005)

did not include the hRFC-B 5V UTR as originally described, but was terminated at position À11 relative to the downstream translational start site in coding exon 1 (designated AUG1).There is no difference between the primary amino acid sequences for the hRFC protein encoded by the À11 construct and that for the construct including the non-coding exon B. Also, in Figure 3, which shows deletion constructs for the hRFC-A1/A2 promoter, the construct labeled hRFC-A1/A2(À1177) is mislabeled.It should be labeled as hRFC-A1/ A2(À1124), corresponding to positions À1124 to À987.As with the other deletion constructs, hRFC-A1/A2(À1124) was prepared by PCR from genomic template with sense (5V -ACTGCCTCGAGCTGGAGACATGATT CTGATAAGTGGACAGGCT-3V ) and antisense (5V -CTAGCTAAGCTT GGGCGTGTCTCTTTCAGTCCTGATTCTGCCCAGGA) primers.
水通道蛋白是否与皮肤老化有关?
Journal: British Journal of Dermatology (2022)

Journal Article 水通道蛋白是否与皮肤老化有关? Get access British Journal of Dermatology, Volume 186, Issue 2, 1 February 2022, Page e98, https://doi.org/10.1111/bjd.20926 Published: 01 February 2022
Analysis of Early-Life Growth and Age at Pubertal Onset in US Children
Authors: Izzuddin M. Aris, Wei Perng, Dana Dabelea, Jody M. Ganiban, Chang Liu, Kristine Marceau, Olivia C. Robertson, Christine W. Hockett, Nicole L. Mihalopoulos, Xiangrong Kong, Megan M. Herting, T. Michael O’Shea, Elizabeth T. Jensen, Marie-France Hivert, Emily Oken, Akram Alshawabkeh, Judy Aschner, Clancy Blair, Carlos Camargo, Sean Deoni, Cristiane Duarte, Anne Dunlop, Amy Elliott, Assiamira Ferrara, James Gern, Carrie Breton, Irva Hertz-Picciotto, Alison Hipwell, Margaret Karagas, Catherine Karr, Barry Lester, Leslie Leve, Johnnye Lewis, Scott Weiss, Cynthia McEvoy, Craig Newschaffer, Thomas O’Connor, Jean Kerver, Julie Herbstman, Susan Schantz, Joseph Stanford, Leonardo Trasande, Rosalind Wright
Journal: JAMA Network Open (2022)

Earlier pubertal onset may be associated with an increased risk of chronic diseases. However, the extent to which growth in the first 5 years of life-an important developmental life stage that lays the foundation for later health outcomes-is associated with pubertal onset remains understudied.
Predictors of Safety for Preschool Peanut Oral Immunotherapy that can help inform a Personalized Medicine Approach
Authors: Duva Karunakaran, Edmond Chan, Qian Zhang, Jeffrey Bone, Stuart Carr, Sandeep Kapur, Gregory Rex, Mary McHenry, Scott Cameron, Victoria Cook, Sara Leo, Tiffany Wong, Timothy Vander Leek, Thomas Gerstner, Joanne Yeung, Elissa Abrams, Raymond Mak, Kyla Hildebrand, Stephanie Erdle, Lianne Soller
Journal: Journal of Allergy and Clinical Immunology (2022)
Orvosi Hetilap, Budapest
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Data Errors in Results Section
Journal: JAMA Network Open (2022)

Wade Thompson, PharmD, PhD; Lucas Morin, PhD; Dorte Ejg Jarbøl, MD, PhD; Jacob Harbo Andersen, MSc; Martin Thomsen Ernst, MSc; Jesper Bo Nielsen, PhD; Peter Haastrup, MD, PhD; Morten Schmidt, MD, PhD; Anton Pottegård, MScPhm, PhD, DMSc
Adcitmer <sup>®</sup> 是 Merkel 细胞癌的潜在治疗方法
Journal: British Journal of Dermatology (2022)

Journal Article Adcitmer® 是 Merkel 细胞癌的潜在治疗方法 Get access British Journal of Dermatology, Volume 186, Issue 2, 1 February 2022, Page e102, https://doi.org/10.1111/bjd.20930 Published: 01 February 2022
CRIME AND INSANITY.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Iran in transition
Authors: Goodarz Danaei, Farshad Farzadfar, Roya Kelishadi, Arash Rashidian, Omid M Rouhani, Shirin Ahmadnia, Alireza Ahmadvand, Mandana Arabi, Ali Ardalan, Mohammad Arhami, Mohammad Hossein Azizi, Moslem Bahadori, Jill Baumgartner, Arash Beheshtian, Shirin Djalalinia, Leila Doshmangir, Ali Akbar Haghdoost, Rosa Haghshenas, Ahmad Reza Hosseinpoor, Farhad Islami, Farin Kamangar, Davood Khalili, Kaveh Madani, Hossein Masoumi-Asl, Ali Mazyaki, Ali Mirchi, Ehsan Moradi, Touraj Nayernouri, Debbie Niemeier, Amir-Houshang Omidvari, Niloofar Peykari, Farhad Pishgar, Mostafa Qorbani, Kazem Rahimi, Afarin Rahimi-Movaghar, Fahimeh Ramezani Tehrani, Nazila Rezaei, Saeid Shahraz, Amirhossein Takian, Ali Tootee, Majid Ezzati, Hamid Reza Jamshidi, Bagher Larijani, Reza Majdzadeh, Reza Malekzadeh
Journal: The Lancet (2019)
Digging Deeper for the Differential Diagnosis of Negative P Waves in Lead I—Reply
Authors: Qinghua Chang, Guofeng Wang, Yuanzhe Jin
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Adcitmer <sup>®</sup> is a potential treatment for Merkel cell carcinoma
Journal: British Journal of Dermatology (2022)

Journal Article Adcitmer® is a potential treatment for Merkel cell carcinoma Get access British Journal of Dermatology, Volume 186, Issue 2, 1 February 2022, Page e89, https://doi.org/10.1111/bjd.20917 Published: 01 February 2022
Efficacy of Anti-Allergen Therapeutics in Preclinical Allergy Model Systems Correlate with Symptomatic Relief in a Clinical Setting
Authors: Amanda Atanasio, Abigail von Recklinghausen, Claire Qiufan Wang, Michelle DeVeaux, Li-Hong Ben, Jennifer Maloney, Mohamed Kamal, Meagan O’Brien, Allen Radin, Andrew Murphy, Matthew Sleeman, Jamie Orengo
Journal: Journal of Allergy and Clinical Immunology (2022)
THE CONQUEST OF THE MOSQUITO.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epigenetic age acceleration in obstructive sleep apnoea is reversible with adherent treatment
Authors: Rene Cortese, David Sanz-Rubio, Leila Kheirandish-Gozal, José Maria Marin, David Gozal
Journal: European Respiratory Journal (2022)

<b>Current findings support the conceptual framework that OSA promotes systemic senescence that is reversible with treatment, and that elucidation of the cellular and molecular mechanisms involved may underpin unique personalised therapeutic opportunities</b> https://bit.ly/32bhPq8
<TITLE>Diagnosing and treating pneumonia</TITLE>
Journal: JAMA (2000)

The bacteria or virus that causes pneumonia is spread when an infected person coughs, sneezes or comes in close contact with another person. WHAT IS PNEUMONIA?Pneumonia is a serious infection or inflammation of the lungs caused by a virus, bacterium, or fungus.The bacterium known as Pneumococcus is the most common cause of bacterial pneumonia.Symptoms of pneumonia include fever, chills, cough, shortness of breath, chest pain, and increased sputum (mucus) production. JAMA PATIENT PAGE Diagnosing and treating pneumoniaThe JAMA Patient Page is a public service of JAMA and the AMA.The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis.For specific information concerning your personal medical condition, JAMA and the AMA suggest that you consult your physician.This page may be reproduced noncommercially by physicians and other health care professionals to share with patients.Any other reproduction is subject to AMA approval.
Maternal Prenatal Inflammation Is Associated With Offspring Childhood Asthma
Authors: Yih-Chieh Chen, Kathleen Lee-Sarwar, Hooman Mirzakhani, Hanna Knihtila, Rachel Kelly, Nancy Laranjo, Raina Fichorova, Ngan Luu, Scott Weiss, Augusto Litonjua
Journal: Journal of Allergy and Clinical Immunology (2022)
Nationwide Shortage of Tuberculin Skin Test Antigens: CDC Recommendations for Patient Care and Public Health Practice
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

CDC is expecting a 3-10 month nationwide shortage of Aplisol, a product of Par Pharmaceuticals, and one of two purified-protein derivative (PPD) tuberculin antigens licensed by the Food and Drug Administration (FDA) for use in performing tuberculin skin tests. This time frame is the manufacturer's current estimate and is subject to change. The manufacturer notified CDC that they anticipate an interruption of supply of Aplisol 5 mL (50 multidose vials) beginning in June 2019, followed by an interruption of the supply of Aplisol 1 mL (10 multidose vials) in November 2019. The expected shortage of Aplisol 1 mL could occur before November 2019 if demand increases before then. Information on the status of this supply interruption will be updated at FDA's Center for Biologics Evaluation and Research-Regulated Products: Current Shortages website (https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cber-regulated-products-current-shortages). This report includes CDC recommendations for mitigating a reduction in tuberculosis (TB) testing capability resulting from the anticipated Aplisol shortage (1).
Issue Information
Journal: Medicinal Research Reviews (2021)

Aims and Scope:The journal publishes timely critical reviews of topics related to medicinal research, broadly defined, to which the authors have made significant contributions.Appropriate topics include, but are not limited to, the underlying pathophysiology of important diseases and disease vectors; therapeutic approaches to the treatment of various diseases; the properties of molecular targets for therapeutic agents; important new methodologies facilitating the search for therapies; genomics and proteomics; structure-activity correlations of drug series; the development of new imaging and diagnostic tools; drug metabolism; drug delivery; and chemical, pharmacological, pharmacokinetic, pharmacodynamic, and clinical characteristics of important drugs.Articles are mainly solicited by the editors; however, voluntary contributions are also encouraged.In the latter case, potential authors are asked to contact the Editor-in-Chief with an outline before beginning to write in order to avoid duplication of effort and to ensure suitability of the topic and the level of coverage.
General and Abdominal Adiposity and Mortality in Mexico City
Authors: Louisa Gnatiuc, Jesus Alegre-Díaz, Rachel Wade, Raúl Ramirez-Reyes, Roberto Tapia-Conyer, Adrián Garcilazo-Ávila, Erwin Chiquete, Carlos Gonzáles-Carballo, Martha Solano-Sanchez, Robert Clarke, Rory Collins, William G. Herrington, Michael Hill, Sarah Lewington, Richard Peto, Jonathan R. Emberson, Pablo Kuri-Morales
Journal: Annals of Internal Medicine (2019)

Some reports suggest that body mass index (BMI) is not strongly associated with mortality in Hispanic populations.To assess the causal relevance of adiposity to mortality in Mexican adults, avoiding reverse causality biases.Prospective study.2 Mexico City districts.159 755 adults aged 35 years and older at recruitment, followed for up to 14 years. Participants with a hemoglobin A1c level of 7% or greater, diabetes, or other chronic diseases were excluded.BMI, waist-to-hip ratio, waist circumference, and cause-specific mortality. Cox regression, adjusted for confounders, yielded mortality hazard ratios (HRs) after at least 5 years of follow-up and before age 75 years.Among 115 400 participants aged 35 to <75 years at recruitment, mean BMI was 28.0 kg/m2 (SD, 4.1 kg/m2) in men and 29.6 kg/m2 (SD, 5.1 kg/m2) in women. The association of BMI at recruitment with all-cause mortality was J-shaped, with the minimum at 25 to <27.5 kg/m2. Above 25 kg/m2, each 5-kg/m2 increase in BMI was associated with a 30% increase in all-cause mortality (HR, 1.30 [95% CI, 1.24 to 1.36]). This association was stronger at ages 40 to <60 years (HR, 1.40 [CI, 1.30 to 1.49]) than at ages 60 to <75 years (HR, 1.24 [CI, 1.17 to 1.31]) but was not materially affected by sex, smoking, or other confounders. The associations of mortality with BMI and waist-to-hip ratio were similarly strong, and each was weakened only slightly by adjustment for the other. Waist circumference was strongly related to mortality and remained so even after adjustment for BMI and hip circumference.Analyses were limited to mortality.General, and particularly abdominal, adiposity were strongly associated with mortality in this Mexican population.Mexican Health Ministry, Mexican National Council of Science and Technology, Wellcome Trust, Medical Research Council, and Kidney Research UK.
Nordisk Medicin, Stockholm
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Retraction Note: Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4
Authors: Shaowei Wang, Boyang Li, Victoria Solomon, Alfred Fonteh, Stanley I. Rapoport, David A. Bennett, Zoe Arvanitakis, Helena C. Chui, Carol Miller, Patrick M. Sullivan, Hoau-Yan Wang, Hussein N. Yassine
Journal: Molecular Neurodegeneration (2022)

This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13024-021-00438-3.
Vitamin D Promotes Vascular Regeneration
Authors: Michael Sze Ka Wong, Matthias S. Leisegang, Christoph Kruse, Juri Vogel, Christoph Schürmann, Nathalie Dehne, Andreas Weigert, Eva Herrmann, Bernhard Brüne, Ajay M. Shah, Dieter Steinhilber, Stefan Offermanns, Geert Carmeliet, Klaus Badenhoop, Katrin Schröder, Ralf P. Brandes
Journal: Circulation (2014)

Vitamin D deficiency in humans is frequent and has been associated with inflammation. The role of the active hormone 1,25-dihydroxycholecalciferol (1,25-dihydroxy-vitamin D3; 1,25-VitD3) in the cardiovascular system is controversial. High doses induce vascular calcification; vitamin D3 deficiency, however, has been linked to cardiovascular disease because the hormone has anti-inflammatory properties. We therefore hypothesized that 1,25-VitD3 promotes regeneration after vascular injury.In healthy volunteers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circulating CD45-CD117+Sca1+Flk1+ angiogenic myeloid cells, which are thought to promote vascular regeneration. Similarly, in mice, 1,25-VitD3 (100 ng/kg per day) increased the number of angiogenic myeloid cells and promoted reendothelialization in the carotid artery injury model. In streptozotocin-induced diabetic mice, 1,25-VitD3 also promoted reendothelialization and restored the impaired angiogenesis in the femoral artery ligation model. Angiogenic myeloid cells home through the stromal cell-derived factor 1 (SDF1) receptor CXCR4. Inhibition of CXCR4 blocked 1,25-VitD3-stimulated healing, pointing to a role of SDF1. The combination of injury and 1,25-VitD3 increased SDF1 in vessels. Conditioned medium from injured, 1,25-VitD3-treated arteries elicited a chemotactic effect on angiogenic myeloid cells, which was blocked by SDF1-neutralizing antibodies. Conditional knockout of the vitamin D receptor in myeloid cells but not the endothelium or smooth muscle cells blocked the effects of 1,25-VitD3 on healing and prevented SDF1 formation. Mechanistically, 1,25-VitD3 increased hypoxia-inducible factor 1-α through binding to its promoter. Increased hypoxia-inducible factor signaling subsequently promoted SDF1 expression, as revealed by reporter assays and knockout and inhibitory strategies of hypoxia-inducible factor 1-α.By inducing SDF1, vitamin D3 is a novel approach to promote vascular repair.